← All trials
NCT04621058
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 9, 2020
- Primary completion
- Nov 30, 2021
- Completion date
- Nov 30, 2021
- First posted
- Nov 9, 2020
- Last posted
- Dec 23, 2020
- Enrollment
- 108
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Bioaraba Health Research InstituteLead sponsor
- Fundación Eduardo AnituaCollaborator
- Bioaraba Health Research InstituteOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.